AZD6244 (ARRY-142886), a novel, selective, ATP-uncompetitive inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2), has shown activity in nanomolar concentrations against isolated MEK enzyme and numerous cancer cell lines [1]. Here, MAP2K1 is linked to cancer.